NY-MOODY'S/METLIFE
Moody’s Corporation, the world’s leading source of bold, clear and perceptive insights on exponential risk, announced today that it has been named an Official Cornerstone Partner of MetLife Stadium, home of the New York Jets and New York Giants.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423976836/en/
(Graphic: Business Wire)
As part of the multi-year partnership, Moody’s branding will be a mainstay at MetLife Stadium events, extending throughout the stadium with in-bowl signage and digital displays. Guests will first be greeted at the Moody’s Gate (pictured above) and then pass through an activation area on the plaza. Moody’s is also the naming rights partner of the Moody’s Commissioners Club, a spectacular private space in the Stadium offering guests unparalleled views and unique experiences at events.
“In trying to find organizations that align with Moody’s renewed brand of decoding complexity and finding a path forward in the face of risk or adversity, we couldn’t think of better partners than MetLife Stadium and the New York Giants and New York Jets,” said Christine Elliott, Chief Corporate Affairs Officer of Moody’s. “These institutions continually demonstrate what it takes to triumph over adversity, show us how to address complexity through teamwork and collaboration, and inspire and entertain us with each and every play. We are honored to join together with these venerable partners as the new season begins to unfold, starting this Thursday with the NFL Draft.”
“We are honored that Moody’s has chosen MetLife Stadium to showcase its new brand platform,” said Ron VanDeVeen, President and CEO of MetLife Stadium. “Having a reputable, New York-based company like Moody’s fits in perfectly with our gameday environment.”
“MetLife Stadium has been the center of entertainment since it opened in 2010,” said Hymie Elhai, President of the New York Jets. “Welcoming a new cornerstone partner like Moody’s will elevate our fan experience from the moment they enter the stadium at the Moody’s Gate and will provide an enhanced experience for our Moody’s Commissioners Club guests. We are excited to kickoff this partnership and work together on ways to reinforce our commitment to our fans.”
“Moody’s exemplifies everything we look for in a Cornerstone partner and we are thrilled to welcome them to MetLife Stadium,” said John Mara, New York Giants President and CEO. “We look forward to developing our new partnership and engaging fans across stadium events and throughout our shared hometown.”
The partnership is part of Moody’s new global branding campaign, defining Moody’s as a category of one. In a world shaped by increasingly interconnected risks, it is more difficult than ever for leaders to act with certainty. Organizations, companies, and governments need to go beyond data into context, and to go beyond context into meaning. That’s where Moody’s is in a category by itself. Through its vast data estate and unparalleled insights and analytics, Moody’s provides a compass for understanding complexity, helping customers decode risk, unlock opportunity, and inform a clear path forward in an era of exponential risk.
The financial terms of the partnership were not disclosed.
For more information, visit www.moodys.com.
About Moody’s Corporation
In a world shaped by increasingly interconnected risks, Moody’s (NYSE: MCO) data, insights, and innovative technologies help customers develop a holistic view of their world and unlock opportunities. With a rich history of experience in global markets and a diverse workforce of 15,000 across more than 40 countries, Moody’s gives customers the comprehensive perspective needed to act with confidence and thrive. Learn more at www.moodys.com.
About MetLife Stadium
MetLife Stadium, located in East Rutherford, NJ, is the home of the New York Jets and New York Giants and is one of the largest stadiums in the NFL (82,500). The stadium hosts the world’s biggest events on the world’s biggest stage and will host the FIFA World Cup 26™ Final and 7 other matches throughout the tournament. The venue annually ranks as one of the busiest stadiums in the world and has been named “Highest Grossing Stadium of the Year” 9 times by Billboard. Event highlights include Super Bowl XLVIII, NHL Stadium Series, WrestleMania, Copa America Centenario Final, 2021 Army-Navy Game, and many concerts, college football games, and international soccer matches.
About the New York Giants
A cornerstone franchise of the National Football League, the New York Football Giants began play in 1925. The Giants have won eight championships: 1927, 1934, 1938, 1956, 1986, 1990, 2007 and 2011. After twice winning two titles in five years, the Giants are the only NFL franchise with Super Bowl victories in four consecutive decades. Headquartered at the Quest Diagnostics Training Center in East Rutherford, N.J., the Giants enter their 100th season of play this fall.
About the New York Jets
The New York Jets were founded in 1959 as the New York Titans, an original member of the American Football League (AFL). The Jets won Super Bowl III, defeating the NFL’s Baltimore Colts in 1969. In 1970, the franchise joined the National Football League in the historic AFL–NFL merger that set the foundation for today’s league. As part of a commitment to its fan base through innovation and experiences, the team has created initiatives such as, its trailblazing Jets Rewards program, a state-of-the-art mobile app, and 1JD Entertainment, a comprehensive content platform that gives fans greater access to the team across all digital and social platforms. The organization takes great pride in a long-standing, year-round commitment to their community. These programs are funded by the New York Jets Foundation and look to positively influence the lives of young men and women in the tri-state area, particularly in disadvantaged communities. The organization supports the efforts of the Lupus Research Alliance, youth football and numerous established charitable organizations and causes sponsored by the NFL. The New York Jets play in MetLife Stadium, which opened in 2010, and are headquartered at the Atlantic Health Jets Training Center in Florham Park, New Jersey. For more information about the New York Jets visit newyorkjets.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423976836/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom